drugset / Trial / NCT06857786

Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Patients

NCT06857786

Phase 1 Not yet recruiting 48 enrolled Peking University
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and tolerability of satri-cel as consolidation therapy after postoperative adjuvant therapy in patients with resected gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

Timeline

Start
2025-03-10
Primary completion
2027-06-30
Completion
2030-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Satricabtagene autoleucel Cell therapy 2.5e+08 cells